The company reported a global recovery rate of 84.9% for the quarter, showing steady improvement from 79.3% in April to 88.0% in June. Monthly production also demonstrated consistent growth, rising ...

Investing.com -- Kezar Life Sciences Inc (NASDAQ: KZR) stock gained 4% after the FDA lifted a partial clinical hold on its completed Phase 2a trial evaluating zetomipzomib in patients with autoimmune ...